Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective

**Background:** Cow’s milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow’s milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. **Objectives:** This s...

Full description

Bibliographic Details
Main Authors: Ana Teresa Paquete, Rui Martins, Mark P. Connolly, Badriul Hegar, Zakiudin Munasir, Stephanus Stephanus
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2022-09-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://jheor.org/article/36407-managing-cow-s-milk-protein-allergy-in-indonesia-a-cost-effectiveness-analysis-of-hypoallergenic-milk-formulas-from-the-private-payers-perspective
_version_ 1798002214991560704
author Ana Teresa Paquete
Rui Martins
Mark P. Connolly
Badriul Hegar
Zakiudin Munasir
Stephanus Stephanus
author_facet Ana Teresa Paquete
Rui Martins
Mark P. Connolly
Badriul Hegar
Zakiudin Munasir
Stephanus Stephanus
author_sort Ana Teresa Paquete
collection DOAJ
description **Background:** Cow’s milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow’s milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. **Objectives:** This study aims to compare the cost-effectiveness of extensively hydrolyzed casein formula with _Lacticaseibacillus rhamnosus_ Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), amino acid formula, and soy formula in the first-line management of cow’s milk protein allergy in non-breastfed children in Indonesia. **Methods:** A trial-based decision analytic cohort model was adapted to simulate the occurrence of cow’s milk protein allergy symptoms or being symptom free. The model was based on a prospective nonrandomized study that followed up children for 36 months. Costs and health consequences were discounted at 3% annually. Resources required to manage cow’s milk protein allergy and unit costs for clinical appointments and exams were based on a panel of 15 clinicians, from a private payers’ perspective. Other unit costs were based on publicly available national data. Results were reported as cost per additional child free from allergic manifestations or per additional immunotolerant child at 3 years, and per life-years under the same conditions. Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. **Results:** Children receiving EHCF+LGG were associated with more symptom-free time, a higher probability of cow’s milk tolerance at 3 years, and lower healthcare resources and transportation use when compared with children receiving other formulas (with 38%-49% lower costs). Formula costs were lower for soy, but EHCF+LGG was predicted to save 9% and 54% of overall costs compared with extensively hydrolyzed whey formula and amino acid formula, respectively. Results were robust to sensitivity analyses. **Conclusion:** Use of EHCF+LGG resulted in more symptom-free time and the highest 3-year probability of cow’s milk tolerance. It also led to healthcare resource and transportation savings when compared with other hypoallergenic milk formulas. Soy formula remained an alternative if formula price represents a major constraint.
first_indexed 2024-04-11T11:48:35Z
format Article
id doaj.art-563667d312eb4d2390722fd451cd117a
institution Directory Open Access Journal
issn 2327-2236
language English
last_indexed 2024-04-11T11:48:35Z
publishDate 2022-09-01
publisher Columbia Data Analytics, LLC
record_format Article
series Journal of Health Economics and Outcomes Research
spelling doaj.art-563667d312eb4d2390722fd451cd117a2022-12-22T04:25:26ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362022-09-01Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ PerspectiveAna Teresa PaqueteRui MartinsMark P. ConnollyBadriul HegarZakiudin MunasirStephanus Stephanus**Background:** Cow’s milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow’s milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. **Objectives:** This study aims to compare the cost-effectiveness of extensively hydrolyzed casein formula with _Lacticaseibacillus rhamnosus_ Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), amino acid formula, and soy formula in the first-line management of cow’s milk protein allergy in non-breastfed children in Indonesia. **Methods:** A trial-based decision analytic cohort model was adapted to simulate the occurrence of cow’s milk protein allergy symptoms or being symptom free. The model was based on a prospective nonrandomized study that followed up children for 36 months. Costs and health consequences were discounted at 3% annually. Resources required to manage cow’s milk protein allergy and unit costs for clinical appointments and exams were based on a panel of 15 clinicians, from a private payers’ perspective. Other unit costs were based on publicly available national data. Results were reported as cost per additional child free from allergic manifestations or per additional immunotolerant child at 3 years, and per life-years under the same conditions. Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. **Results:** Children receiving EHCF+LGG were associated with more symptom-free time, a higher probability of cow’s milk tolerance at 3 years, and lower healthcare resources and transportation use when compared with children receiving other formulas (with 38%-49% lower costs). Formula costs were lower for soy, but EHCF+LGG was predicted to save 9% and 54% of overall costs compared with extensively hydrolyzed whey formula and amino acid formula, respectively. Results were robust to sensitivity analyses. **Conclusion:** Use of EHCF+LGG resulted in more symptom-free time and the highest 3-year probability of cow’s milk tolerance. It also led to healthcare resource and transportation savings when compared with other hypoallergenic milk formulas. Soy formula remained an alternative if formula price represents a major constraint.https://jheor.org/article/36407-managing-cow-s-milk-protein-allergy-in-indonesia-a-cost-effectiveness-analysis-of-hypoallergenic-milk-formulas-from-the-private-payers-perspective
spellingShingle Ana Teresa Paquete
Rui Martins
Mark P. Connolly
Badriul Hegar
Zakiudin Munasir
Stephanus Stephanus
Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
Journal of Health Economics and Outcomes Research
title Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
title_full Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
title_fullStr Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
title_full_unstemmed Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
title_short Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
title_sort managing cow s milk protein allergy in indonesia a cost effectiveness analysis of hypoallergenic milk formulas from the private payers perspective
url https://jheor.org/article/36407-managing-cow-s-milk-protein-allergy-in-indonesia-a-cost-effectiveness-analysis-of-hypoallergenic-milk-formulas-from-the-private-payers-perspective
work_keys_str_mv AT anateresapaquete managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective
AT ruimartins managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective
AT markpconnolly managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective
AT badriulhegar managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective
AT zakiudinmunasir managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective
AT stephanusstephanus managingcowsmilkproteinallergyinindonesiaacosteffectivenessanalysisofhypoallergenicmilkformulasfromtheprivatepayersperspective